| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/28/2011 | US20110097359 Production of diphtheria toxin |
| 04/28/2011 | US20110097358 RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
| 04/28/2011 | US20110097357 Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| 04/28/2011 | US20110097355 Virus-like particles as vaccines for paramyxovirus |
| 04/28/2011 | US20110097354 System for the expression of peptides on the bacterial surface |
| 04/28/2011 | US20110097353 Poultry viral materials and methods related thereto |
| 04/28/2011 | US20110097352 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| 04/28/2011 | US20110097351 Compounds for treating beta-amyloidoses |
| 04/28/2011 | US20110097350 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 04/28/2011 | US20110097349 Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| 04/28/2011 | US20110097348 Protein Formulation |
| 04/28/2011 | US20110097347 Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) |
| 04/28/2011 | US20110097346 Dendritic Cells |
| 04/28/2011 | US20110097345 Novel dosing regimen and method of treatment |
| 04/28/2011 | US20110097344 Compositions, Methods for Treatment, and Diagnoses of Autoimmunity-Related Disorders and Methods for Making Such Compositions |
| 04/28/2011 | US20110097343 Diagnosis and therapy of hematological malignancies |
| 04/28/2011 | US20110097342 Binding agents |
| 04/28/2011 | US20110097341 Treatment of Chronic Prostatitis |
| 04/28/2011 | US20110097340 Fully human anti-vegf antibodies and methods of using |
| 04/28/2011 | US20110097339 Compositions monovalent for CD28 binding and methods of use |
| 04/28/2011 | US20110097338 Use of Substances for Sensitization of Tumor Cells to Radiation and/or Chemotherapy |
| 04/28/2011 | US20110097337 Composition for eliciting a specific ctl response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| 04/28/2011 | US20110097336 Methods for modulating mannose content of recombinant proteins |
| 04/28/2011 | US20110097335 Abc transporter protein expression inhibitor |
| 04/28/2011 | US20110097334 Novel Marker Genes for Regulatory T Cells from Human Blood |
| 04/28/2011 | US20110097333 Therapeutic and diagnostic agents |
| 04/28/2011 | US20110097332 Composition and Method of Use for HCV Immunization |
| 04/28/2011 | US20110097331 Antibodies that bind both il-17a and il-17f and methods of using the same |
| 04/28/2011 | US20110097330 Novel Gene Disruptions, Compostitions and Methods Relating Thereto |
| 04/28/2011 | US20110097329 Compositions and methods for treating cancer and modulating stress granule formation |
| 04/28/2011 | US20110097328 Methods and compositions for increasing the activity of inhibitory rna |
| 04/28/2011 | US20110097327 Product and method for treatment of conditions associated with receptor-desensitization |
| 04/28/2011 | US20110097326 Anti-trkb antibodies |
| 04/28/2011 | US20110097325 Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases |
| 04/28/2011 | US20110097324 Compositions and methods for modulating nicotinic/nmda receptor function |
| 04/28/2011 | US20110097323 Her2/neu-Specific Antibodies and Methods of Using Same |
| 04/28/2011 | US20110097322 Partially loaded antibodies and methods of their conjugation |
| 04/28/2011 | US20110097321 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| 04/28/2011 | US20110097320 4-aminoquinazoline derivatives and methods of use thereof |
| 04/28/2011 | US20110097319 Antibody Capable of Binding Specifically to AB-Oligomer, and Use Thereof |
| 04/28/2011 | US20110097318 Solid-State Protein Formulation |
| 04/28/2011 | US20110097317 Thioredoxin Interacting Protein (TXNIP) As Regulator Of Vascular Function |
| 04/28/2011 | US20110097314 Method for producing a composition for promoting survival of transplanted hematopoietic stem cell |
| 04/28/2011 | US20110097312 Anti-cancer vaccines |
| 04/28/2011 | US20110097306 Oral formulations of cladribine |
| 04/28/2011 | US20110097270 Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus |
| 04/28/2011 | US20110097262 NOVEL ANTI-cMET ANTIBODY |
| 04/28/2011 | US20110097261 Amigo-2-inhibitors for treating, diagnosing or detecting cancer |
| 04/28/2011 | CA2778707A1 Cancer immunotherapy and method of treatment |
| 04/28/2011 | CA2778613A1 Methods and compositions for panic disorders |
| 04/28/2011 | CA2778483A1 Modulation of axon degeneration |
| 04/28/2011 | CA2778442A1 Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
| 04/28/2011 | CA2778401A1 Integrin alpha 8-beta 1-specific monoclonal antibody |
| 04/28/2011 | CA2778359A1 Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof |
| 04/28/2011 | CA2778334A1 Anti-cd3 antibody dosing in autoimmune disease |
| 04/28/2011 | CA2778331A1 Methods of using anti-cd3 antibodies to prevent weight gain |
| 04/28/2011 | CA2778176A1 Dual variable domain immunoglobulins and uses thereof |
| 04/28/2011 | CA2778158A1 Compositions, methods for treatment, and diagnoses of autoimmunity-related disorders and methods for making such compositions |
| 04/28/2011 | CA2778084A1 Modified variable domain molecules and methods for producing and using same |
| 04/28/2011 | CA2777883A1 Medical utility of glycan-binding proteins and glycans |
| 04/28/2011 | CA2777159A1 Detection of a circovirus in calves suffering from bovine neonatal pancytopenia |
| 04/28/2011 | CA2775924A1 Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| 04/28/2011 | CA2775806A1 Novel dosing regimen and method of treatment |
| 04/28/2011 | CA2775595A1 Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
| 04/28/2011 | CA2774032A1 Anti-gcc antibody molecules and related compositions and methods |
| 04/28/2011 | CA2773356A1 Compositions and methods for treating inflammation and fibrosis |
| 04/28/2011 | CA2771817A1 Modulators of hepatocyte growth factor activator |
| 04/27/2011 | EP2315028A1 PODXL protein in colorectal cancer |
| 04/27/2011 | EP2314719A1 S. pneumoniae antigens |
| 04/27/2011 | EP2314718A1 S. pneumoniae antigens |
| 04/27/2011 | EP2314716A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/27/2011 | EP2314712A1 Expression vectors encoding epitopes of antigens and methods for their design |
| 04/27/2011 | EP2314697A1 Streptococcus pneumoniae proteins and nucleic acids |
| 04/27/2011 | EP2314696A1 Therapeutic uses of human Interleukin-B50 antagonist. |
| 04/27/2011 | EP2314695A2 Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
| 04/27/2011 | EP2314694A2 BAFF receptor (BCMA), an immunoregulatory agent |
| 04/27/2011 | EP2314686A1 Cells producing antibody compositions |
| 04/27/2011 | EP2314685A1 Cells producing antibody compositions |
| 04/27/2011 | EP2314676A1 Compositions and methods for the treatment of immune related diseases |
| 04/27/2011 | EP2314630A1 Method of producing immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes |
| 04/27/2011 | EP2314629A1 Recombinant production of mixtures of antibodies |
| 04/27/2011 | EP2314628A1 Anti-cd27 antibody |
| 04/27/2011 | EP2314627A2 Method for the treatment of multiple sclerosis |
| 04/27/2011 | EP2314625A1 Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| 04/27/2011 | EP2314624A2 Human antibody molecules for IL-13 |
| 04/27/2011 | EP2314623A1 IL-1beta binding antibodies and fragments thereof |
| 04/27/2011 | EP2314621A1 Binding molecules capable of neutralizing rabies virus and uses thereof |
| 04/27/2011 | EP2314620A1 Binding molecules capable of neutralizing rabies virus and uses thereof |
| 04/27/2011 | EP2314619A1 Anti-orthopoxvirus recombinant polyclonal antibody |
| 04/27/2011 | EP2314612A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314611A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314610A2 Differential in tumour gene products and use of same |
| 04/27/2011 | EP2314604A2 Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof |
| 04/27/2011 | EP2314603A2 Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof |
| 04/27/2011 | EP2314349A1 Anti-viral griffithsin compounds, compositions, and methods of use |
| 04/27/2011 | EP2314322A1 Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor |
| 04/27/2011 | EP2314318A1 CD80 antibody for use in combination with chemotherapeutics to treat B cell malignancies |
| 04/27/2011 | EP2314317A2 Anti-glypican 3 antibody |
| 04/27/2011 | EP2314316A1 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
| 04/27/2011 | EP2314315A1 A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders |